CGEN and AZN Related Headlines
Go Back- DATROWAY plus rilvegostomig shows tumor responses in urothelial cancer trial
- DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial

